Everand Logo

Welcome to Everand!

  • STAT

    How fast can biotech come up with a vaccine for the latest outbreak?

    History suggests the road to a vaccine for the new pneumonia-causing virus will be long, unpredictable, and expensive.
    by Damian Garde Jan 24, 2020 3 minutes
    Commuters in Hong Kong wear face masks as a precautionary measure to protect against the possible spread of a new pneumonia-causing virus.

    The deadly outbreak of a novel coronavirus has sparked a race among biotech companies, each claiming that its technology can quickly whip up a vaccine to quell a potential crisis. But history suggests the road ahead will be long, unpredictable, and expensive.

    Moderna Therapeutics and Inovio Pharmaceuticals are among the companies turning their focus to the emerging virus, called 2019-nCoV. Each has received millions in funding from the Coalition for Epidemic Preparedness Innovations, a global organization that has

    You’re reading a preview, subscribe to read more.

    More from STAT

    STAT2 min read
    STAT+: Brain Biopsies On ‘Vulnerable’ Patients At Mount Sinai Set Off Alarm Bells At FDA, Documents Show
    A STAT Investigation: Brain biopsies on "vulnerable" patients at Mount Sinai set off alarm bells at FDA, documents show.
    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About A Senate Probe Into Novo Pricing, A New UTI Antibiotic, And More
    The U.S. Senate health committee is investigating the prices Novo Nordisk charges for its blockbuster medications Ozempic and Wegovy.
    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About CVS And Humira Biosimilars, Schumer’s Broken Insulin Promise, And More
    New prescriptions for biosimilar versions of Humira, one of the best-selling drugs in the U.S., surged to 36% from just 5% during the first week of April.

    Related Books & Audiobooks